Blocking CCN2/CTGF in the ALS mouse model decreases axon degeneration and preserves the structure of the neuromuscular junction (NMJ) [34]; while in the rat model of muscle overuse, it improves mononeuropathy, decreasing neural fibrosis and sensory decline [60]. Here, CCN2 is linked to amyotrophic lateral sclerosis.